Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary study published Wednesday in the journal Nature. Pancreatic cancer is one ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...

The trial would combine standard surgery and chemotherapy treatments — which are the standard of care for pancreatic cancer — with a customized mRNA vaccine. Each vaccine would be designed ...

In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...